Glucotrack’s Subsidiary Lōkahi Therapeutics Unveils Qare Comparative Health Platform For GLP-1 And Other Treatment Outcomes
Developed Through ai² Accelerator™, Qare™ Is Designed to Enable Users to Compare Their Experiences Against Cohorts of People Like Them, with Additional Drug Classes Expected to FollowLōkahi Therapeutics™, a subsidiary
Glucotrack's subsidiary launched a new platform called Qare. It helps people compare how GLP-1 drugs work for them versus similar people.
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only. Not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.